Levodopa is NOT indicated for normal-pressure hydrocephalus
In this 70-year-old patient with magnetic gait, urinary frequency, and dementia consistent with normal-pressure hydrocephalus (NPH), levodopa should not be used as treatment. The definitive treatment for NPH is CSF diversion through shunting, not dopaminergic therapy 1.
Why Levodopa Fails in NPH
The pathophysiology of NPH involves altered CSF dynamics causing ventricular enlargement and periventricular ischemia—not dopaminergic deficiency. NPH is a potentially reversible etiology of dementia following CSF diversion (shunting), with an estimated prevalence of 3.7% in patients >65 years 1. The clinical improvement occurs through restoration of CSF homeostasis, not through neurotransmitter replacement.
Key Distinguishing Features from Parkinson's Disease
While both conditions can present with gait disturbance, the gait patterns are fundamentally different:
- NPH gait: Broad-based, outward rotated feet, diminished step height, "magnetic" quality
- Parkinson's gait: Narrow-based, shuffling, festinating, responds to external cues 2
Research demonstrates that levodopa is generally ineffective for NPH-related parkinsonism 3. In comparative studies, patients with NPH showed minimal response to external cues (which help Parkinson's patients significantly), and levodopa did not improve the core gait disturbance 2.
The Correct Diagnostic and Treatment Pathway
Immediate Steps:
Obtain brain imaging (MRI preferred over CT) to confirm NPH findings 1, 4:
- Ventriculomegaly (Evans index >0.3)
- Narrowed posterior callosal angle (<90°)
- Effaced sulci at high convexities with widened Sylvian fissures
- Periventricular white matter changes
- Aqueductal flow void on MRI
Perform CSF tap test as the key diagnostic tool 5:
- Remove 30-50 mL CSF
- Reassess gait objectively within hours to days
- Both objective and subjective improvements predict good shunt outcomes
Neurosurgical consultation for shunt placement if tap test positive 1
Critical Pitfall to Avoid
Do not trial levodopa as a diagnostic test for NPH. Approximately 20-57% of NPH patients have comorbid neurodegenerative diseases like Alzheimer's disease 1, and some rare cases may have true comorbid Parkinson's disease 6. However, the primary pathology in NPH—the hydrocephalus itself—does not respond to levodopa 7.
When Levodopa Might Be Considered (Rare Exception)
Only in the exceptional circumstance where a patient has documented comorbid Parkinson's disease (confirmed by dopamine transporter imaging showing reduced striatal uptake) alongside NPH should levodopa be considered 6. Even then, shunt surgery remains the primary treatment for the NPH component.
The Evidence on Dual Pathology
A 2026 case series 6 reported three patients with both hydrocephalus and parkinsonism. Two improved with both levodopa and shunt surgery, but notably, one improved only with levodopa and not with spinal tap—suggesting true Parkinson's disease rather than NPH. In one dual responder, dopamine transporter uptake actually improved postoperatively, and motor symptoms remained stable despite tapering levodopa, indicating the parkinsonism was secondary to hydrocephalus-induced dopaminergic dysfunction.
Bottom Line Treatment Algorithm
For this patient with classic NPH triad:
- Confirm diagnosis: MRI brain without contrast showing NPH features 4
- CSF tap test: Remove 30-50 mL, reassess gait 5
- If positive response: Proceed to ventriculoperitoneal shunt placement 1, 8
- Do NOT use levodopa as it will not address the underlying CSF dynamics 3, 2
Approximately 75% of properly selected NPH patients improve after shunt surgery 8. The FDA-approved indications for levodopa are Parkinson's disease and parkinsonian syndromes—not NPH 7.